ClinicalTrials.gg

Program

ozureprubart

Also written as “JYB1904” and “RPT904”.

Its studies are mostly in Chronic Urticaria · Immune System Diseases · Asthma · Rhinitis, Allergic, Perennial, led by 2 companies.

Furthest: phase 3, since Jan 28, 20267 company-led studies, 5 open or runningNext primary completion: Mar 16, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jemincare64 open or runningphase 3since Jan 28, 2026Jun 29, 2022Jun 7, 2027phase 3 · NCT07402213
GlaxoSmithKline11 open or runningphase 2since Oct 22, 2025Oct 22, 2025Mar 16, 2027phase 2 · NCT07220811
  • Named in GlaxoSmithKline’s own pipeline as ozureprubart GSK6775388, phase 2, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2022First study: phase 1 study in HealthyNew to JemincareJemincare · NCT05449535 · 56 enrolled · China
  2. May 27, 2024Phase 2 study in Allergic AsthmaJemincare · NCT06438757 · 69 enrolled · China
  3. Jun 27, 2024Phase 2 study in Chronic UrticariaJemincare · NCT06509334 · 135 planned · China
  4. Oct 22, 2025GlaxoSmithKline's first study: phase 2 study in Immune System DiseasesNew to GlaxoSmithKlineGlaxoSmithKline · NCT07220811 · 110 enrolled · United States, Australia, Canada
  5. Jan 28, 2026Phase 3 study in Chronic UrticariaPhase 3 reachedJemincare · NCT07402213 · 240 planned · China
  6. Feb 27, 2026Phase 2 study in Rhinitis, Allergic, PerennialJemincare · NCT07459452 · 135 planned
  7. Mar 27, 2026Phase 1 study in Allergic DiseasesJemincare · NCT07513857 · 12 planned

Ahead

  1. Mar 16, 2027Primary completion: phase 2 study in Immune System DiseasesGlaxoSmithKline · NCT07220811
  2. Jun 7, 2027Primary completion: phase 3 study in Chronic UrticariaJemincare · NCT07402213
  3. Jul 30, 2027Primary completion: phase 1 study in Allergic DiseasesJemincare · NCT07513857
  4. Oct 2027Primary completion: phase 2 study in Rhinitis, Allergic, PerennialJemincare · NCT07459452

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07513857Allergic Diseases1Not yet recruitingJemincareJul 30, 202712
NCT07459452Rhinitis, Allergic, Perennial2Not yet recruitingJemincareOct 2027135
NCT07402213Chronic Urticaria · China3RecruitingJemincareJun 7, 2027240
NCT07220811Immune System Diseases · United States, Australia, Canada2Active, not recruitingGlaxoSmithKlineMar 16, 2027110
NCT06509334Chronic Urticaria · China2RecruitingJemincareJul 15, 2026135
NCT06438757Allergic Asthma · China2CompletedJemincareNov 20, 202569
NCT05449535Healthy · China1CompletedJemincareJan 10, 202356

How it is read

Names in the registry

  • “JYB1904”, 8 entries
  • “RPT904”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.